Working document, November 2012. Context



Similar documents
Frequently asked questions on the procedure for the re-assessment of glyphosate within the framework of the EU active substance review

Resources Based, Manufacturing and Consumer Goods Industries Chemicals Industry

TESTIMONY OF DR. STEVEN BRADBURY DIRECTOR, OFFICE OF PESTICIDE PROGRAMS U.S. ENVIRONMENTAL PROTECTION AGENCY

European Conference on Safe Use of Plant Protection Products

Submission of scientific peer-reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009 1, 2

Regulatory Risk Analysis in the European Union, United States, and Canada

How to Influence EU Public Opinion about Agricultural Biotechnology

An Evidence-Based Approach to Reviewing the Science on the Safety of Chemicals in Foods

Guideline on good pharmacovigilance practices (GVP)

GUIDANCE DOCUMENT ON THE EVALUATION OF NEW ACTIVE SUBSTANCE DATA POST APPROVAL

Knowledge. Practical guide to competition damages claims in the UK

European Commission Contract no. FIF : Users Guide to European Regulation in Biotechnology. Final Report, Part I: Complete text

Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015

Environmental Monitoring

Guideline on good pharmacovigilance practices (GVP)

ALFI Code of Conduct for Luxembourg Investment Funds

Ethical Guidelines to Publication of Chemical Research

RKI workshop, Evidence based immunisation. Evidence-based methods for public health

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES

Main Issues on the Further Development of the EC Biocidal Products Directive

Essentials of RESEARCH GOVERNANCE

COMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a RECOMMENDATION OF THE COUNCIL AND OF THE EUROPEAN PARLIAMENT

Maize 1507: toxic and inadequately tested

Anti-Corruption Charter. Preamble

The Society of Actuaries in Ireland

How companies leverage quality and quality certifications to achieve competitive advantage

CLINICAL TRIALS WITH MEDICINES IN EUROPE

The Role and Function of a Data Protection Officer in the European Commission s Proposed General Data Protection Regulation. Initial Discussion Paper

Procurement Reform Bill : Consultation response from the Scottish Fair Trade Forum

Statement of ethical principles for biotechnology in Victoria

Internal Audit Charter

CODE OF ETHICS renaul DrIVE THE CHanGE

Dear readers, Current EFSA co-operation projects. Editorial Dear readers Catherine Geslain-Lanéelle

Policy Recommendations for Managing Risk in Social Innovation

OPTIMISING PATIENT OUTCOMES THROUGH PHYSICIAN EDUCATION

Tackling Europe s bee decline The role veterinarians can play. Federation of Veterinarians of Europe

Centre International de Droit Comparé de l Environnement CIDCE. Comments on the Zero draft of the Post 2015 framework for disaster risk reduction

Stakeholder Guide

OECD WATCH MULTISTAKEHOLDER CONFERENCE 1, April 2005, Brussels Putting the OECD Guidelines for MNEs into Practice

Healthcare Associate Infections Priority Setting Partnership. PROTOCOL 1 st July 2014

Frequently Asked Questions. Unannounced audits for manufacturers of CE-marked medical devices. 720 DM a Rev /10/02

Preparing for Unannounced Inspections from Notified Bodies

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor

Guidelines on the Management of the List of Competent Organisations According to Article 36 of EFSA s Founding Regulation 1

IFAD Policy on Enterprise Risk Management

EASAC Guidelines: Good Practice in the Dialogue between Science Academies and Policy Communities.

MUST-B. EU efforts for the development of a Holistic approach for the Risk Assessment on MUltiple STressors in Bees

The dental profession s peer review program is a process to resolve disputes between a

Business Plan

Ethical Trading Initiative Management Benchmarks

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark

KINGDOM OF SAUDI ARABIA. Capital Market Authority CREDIT RATING AGENCIES REGULATIONS

ACCOUNTABILITY AND DISCLOSURE PUBLICITY AND INFORMATION MATERIALS

ANALYSIS OF THE STAKEHOLDER CONSULTATION ON

5.5 QUALITY ASSURANCE AND QUALITY CONTROL

Job Title: Customer Experience Specialist

Medical Innovation Bill

Compliance Audit Handbook

Mesothelioma Priority Setting Partnership. PROTOCOL November 2013

DRAFT. Erasmus+ Application Form for Accreditation - Call: 2014

Clear, transparent reporting The new auditor s report

Universal Declaration on Bioethics and Human Rights

SOLUTIONS FOR RESEARCHERS. KI EN-C

Taking Part in Research at University Hospitals Birmingham

Promoting the Development of Sustainable Energy Project, Azerbaijan

KEY - Ethical Certifications and Memberships

Info sheet : Considering labour standards in the procurement process

Volunteer Managers National Occupational Standards

Some activities in JRC of relevance for Swedish scientists

Job description and person specification

Global Research Alliance Charter

Paris, 15 June 2013 Response to a public consultation

Suite Overview...2. Glossary...8. Functional Map.11. List of Standards..15. Youth Work Standards 16. Signposting to other Standards...

EEF response to Review of Balance of Competences: Free Movement of Persons

Corporate Governance. The benefits of good practice for private companies in the GCC February 2013

Thematic Report: Annuities. An analysis of the key findings from the FCA s thematic review into the annuities market and guidance for providers.

How to Run Offshore Management Companies and Funds with Substance and Corporate Governance

CONSULTATION PAPER CP 41 CORPORATE GOVERNANCE REQUIREMENTS FOR CREDIT INSTITUTIONS AND INSURANCE UNDERTAKINGS

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART

Response of the German Medical Association

Align Technology. Data Protection Binding Corporate Rules Processor Policy Align Technology, Inc. All rights reserved.

Job Title: Business Continuity and Emergency Planning Support Officer

Development of Environmental Indicators for Monitoring of Genetically Modified Plants

European Forum for Good Clinical Practice Audit Working Party

Principles Governing Academy Relationships with External Sources of Support

Work Experience Schemes: advice for educators on health and safety

INSURANCE ACCOUNTING MIND THE UK GAAP

In terms of food quality, you want to be absolutely confident that the results you get are reliable.

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Norway

Max for main heading 24pt bold Annual Report 2013/14

What the experts say: The consensus of scientific opinion

INSURANCE ACT 2008 CORPORATE GOVERNANCE CODE OF PRACTICE FOR REGULATED INSURANCE ENTITIES

Keeping Costs Under Control

TERMS OF REFERENCE - MAJOR EVENTS PANEL

20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany

FINANCIAL INCLUSION: ENSURING ACCESS TO A BASIC BANK ACCOUNT

(Resolutions, recommendations and opinions) RECOMMENDATIONS COUNCIL

Lobbying: Sweet Smell of Success?

The Code of Good Impact Practice. June 2013

CUMULATIVE AND AGGREGATED EXPOSURE TO PESTICIDES

Transcription:

Social and environmental organisations demand radical overhaul of our food and environmental safety system and of the European Food Safety Authority (EFSA) Working document, November 2012 Context The European Commission is expected to launch a proposal to revise the EFSA Founding regulation 1 in the beginning of 2013. The EU institutions bear great responsibility for the way EFSA functions and the flaws that have been reported over the last ten years. Beyond the founding regulation, that establishes EFSA's building blocks, EU laws dictate that the studies carried out to support the authorisation of risky products like pesticides, food additives and genetically modified foods are done by industry. But EFSA has the power and in the case of pesticides, the legal obligation to balance the risk assessment by also considering data generated by independent scientists. However, such data may or may not be available. Also, EFSA itself is responsible for its policy on how to deal with conflicts of interest among experts, staff and management. This policy has been highly flawed for many years and still is far from perfect. The revision of the founding regulation that touches on EFSA's governance, independence, transparency and scientific quality is a major opportunity to initiate radical change at the agency that is responsible for objective scientific advice on food and environmental safety at EU level. The undersigned organisations make the following urgent demands for change upon the EU institutions and EFSA, to ensure that EFSA fulfils its intended role of providing unbiased and up-to-date scientific advice to protect public health. Many of these demands can be addressed through the founding regulation revision, though not all. 1) Prevent conflicts of interest EFSA's independence policy should effectively exclude people with conflicts of interest from its scientific panels, working groups, scientific committee and staff. EFSA should proactively seek out independent experts and push the EU institutions to grant the agency the means to pay them for their work. Any collaboration with industry and industryaffiliated bodies such as the International Life Sciences Institute (ILSI) should be ended. 1 The current Founding Regulation (EC) No 178/2002 is at:: http://eurlex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexapi!prod!celexnumdoc&lg=en&numdoc=32002r0 178&model=guichett

Declarations of interest should be better scrutinised and those of senior staff members should be available online. The EFSA founding regulation should be revised so as to exclude industry-affiliated people from the Management Board. Independent scientists should be invited to peer review EFSA s guidance documents and opinions and their comments should be made public. This is especially important in cases where conflicts of interest have been exposed about EFSA panel members who have generated guidance documents and opinions in the past. In these cases, even when the conflicted individual has gone, their work remains behind them, and may put public and environmental health at risk. The revolving door should be effectively closed. EFSA staff moving from their position in EFSA to a position in industry or an industry lobby group, or vice versa, should be have a minimum cooling off period of 2 years. Even if formally ended, affiliations with industry related bodies have to be taken into account by assessing conflicts of interest. 2) EU laws should be overhauled so that independent bodies test substances, not industry itself EU laws should be revised to mandate that risk assessments be based on studies carried out independently and paid for through a publicly managed fund. Industry should bear the costs while ensuring that a strict barrier is maintained between industry and EFSA. This will ensure that EFSA has the capacity to protect food and environmental safety. Either independent laboratories could be commissioned to do the testing, or an independent testing commission could be set up. The independent commission could take the company s data on the physical and chemical and/or genetic properties of the substance, confirm it, and do dose-ranging tests independently. In the case of chemicals and pesticides, this would end the current reliance on high, unrealistic dose testing and enable low, realistic doses to be tested over a long period and during vulnerable periods of the organism. This reflects real-life human exposures, which current risk assessment practices often fail to test. 3) A code of scientific practice should be established for EFSA Decisions affecting public health and environment are not only scientific in nature. They should include societal, ethical and economic considerations and involve a wide range of expertise. But insofar as EFSA is tasked with making decisions on the basis of scientific evidence, there should be systems in place to ensure that the evidence is selected and evaluated according to transparent and rigorous scientific procedures. Currently, it is often not clear how EFSA arrives at certain opinions and conclusions: for example, which scientific evidence it has taken into account and why; and which evidence it has discounted, and why. This problem was highlighted, for instance, in the divergence of EFSA s opinion on the safety of bisphenol A from that of the French food safety authority Anses.

EFSA s aim should be to develop policy in the public interest, based on the best available evidence. The objective should be objectivity. Objectivity in science is ensured by transparency and reproducibility. Adherence to these principles can help to minimize bias and to ensure that when controversy arises, it is possible to identify the origins of diverging opinions. EFSA s Founding Regulation should commit it to embracing the best practices to achieve objectivity. This means the establishment of scientifically rigorous, transparent, and replicable methodologies for EFSA s risk assessment work. As well as building public confidence in the risk assessment process, this will also help to minimize the controversy around conflicts of interest that surrounds EFSA. This is because with proper methodologies in place, the identity, interests and biases of an individual or group who carries out the assessment work become less important. The most important factor instead becomes whether the methodology was followed correctly. If it was, then the same verdict would be reached, whoever carried out the assessment. Correct adherence to a rigorous methodology can be easily verified and any mistakes remediated. A code of scientific practice should be established for EFSA reviews, covering: a. how evidence is located and selected, including search parameters, inclusion and exclusion criteria for studies, and strategies for ensuring full capture of relevant evidence, including grey literature; b. how evidence is weighted/de-weighted and evaluated, including a priori and clearly-stated criteria for evaluating the quality of individual studies and overall body of evidence, to ensure maximum use of all available literature; c. acknowledge scientific uncertainty where it exists, possibly in the same way that the IPCC does. EFSA s method of selecting and evaluating data for risk assessment must be systematized. On pesticides and chemicals, EFSA should respect existing EU laws (e.g. the REACH law on chemicals and the pesticides regulation) that give due weight in the risk assessment to studies from the open peer-reviewed scientific literature, rather than favouring industry studies conducted according to OECD/Good Laboratory Practice (GLP) protocols. EFSA s Opinions and Guidance documents show that it often fails to fulfil these requirements. EFSA should develop detailed protocols for the testing of genetically modified organisms (GMOs). In particular, detailed protocols for long-term testing of the food safety of GMOs need to be devised. Where EFSA has the ability to request further (long-term) studies, it must do so on the basis of any uncertainties presented by the data available. EFSA has so far not requested any such studies for GM crops, although phrases acknowledging uncertainties, such as unlikely to be of biological significance, pervade EFSA s assessments of GM crops. While industry studies must continue to be conducted according to OECD protocols and GLP rules, lack of OECD/GLP compliance must not be used as a reason to dismiss or de-weight studies from the mainstream scientific literature, where the peer review process ensures research is of sufficient quality. EFSA must give rigorous scientific arguments for dismissing or de-weighting studies,

especially those finding adverse effects, from the open peer-reviewed scientific literature in the risk assessment. If doubt exists, then the funds available to EFSA could be used to repeat such studies (if necessary, according to agreed protocols) to determine whether the effects are real or artefacts. In the case of GMOs, there is a shortage of scientific research carried out independently of industry. Therefore, companies seeking authorization of GMOs should pay a fee into a publicly administered fund, which would be used to commission independent risk research on their products. 4) Improve transparency and accountability EFSA must make accessible all data and information on which it bases risk assessments. All industry data, and EFSA s decision-making processes on the data, must be available on the internet. Currently, industry data on pesticides is not publicly available, like, for example, on glyphosate. While most industry data on GMOs is available from EFSA upon request, this information should automatically be published on a website. Independent, systematic auditing of EFSA s Opinions and Guidance documents should be carried out to ensure due process is followed. 2 It is not enough for EFSA expert opinions to be evaluated by other EFSA experts; this is an internal and non-independent process. Rules are only effective insofar as they are implemented. Therefore there is a need for an auditing process to ensure due process is followed. The auditing process should be capable of responding to complaints and queries and, like all auditors, should be financially and governmentally independent of the organisation it is auditing. The audits should check that EFSA s decisions are accountable and functioning in the public interest, in order to ensure the public is not exposed to potential harm. 5) Ensure wider participation EFSA expert panels have come under criticism for having too narrow a range of expertise. We recommend that at a minimum, the following types of experts should be actively sought out and invited to serve on EFSA expert panels: to assess human health risks: embryologists, endocrinologists, neurologists, neurodevelopment specialists, reproductive biologists, human geneticists, paediatricians and other clinicians; to assess environmental risks: ecologists, biologists, soil biologists, entomologists, animal welfare and wildlife experts. EFSA experts should be paid. The current practice of using unpaid volunteer experts who 2 This type of audit is not the same as the audit finalised in 2012 by the European Court of Auditors, which focused on EFSA s independence policy in the past. Nor did the evaluation of EFSA's work by accountancy firm Ernst&Young independently verify the quality of EFSA's outputs.

must do their EFSA work in their spare time may favour experts who receive consulting fees or other payment from industry. EFSA experts should be paid out of public funds for their safety assessment work, but industry must cover the cost. However, the money must not go directly from industry to EFSA; a distance must be maintained between industry and EFSA. This could be achieved by setting up a publicly administered fund, which collects fees from industry and then commissions EFSA to carry out or commission the task. A system must be established to include different types of input into the risk assessment, including societal, economic, ethical and environmental factors though this should not be the task of EFSA. While the existing Founding Regulation stipulates that such factors should be taken into account, there is no evidence that this aspect is implemented. Signatories Networks: European Coordination Via Campesina European Professional Beekeepers Association (EWIV) Friends of the Earth Europe IFOAM EU Group HEAL (Health and Environment Alliance) Greenpeace European Unit Pesticide Action Network Europe Organisations: ASEED Europe, Netherlands BUND, Friends of the Earth Germany Cancer Prevention and Education Society (CPES), UK Corporate Europe Observatory Demeter International Earth Open Source, UK FIRAB, Italy Fondation Sciences Citoyennes, France Food & Water Europe GMWatch, UK Platform Aarde Boer Consument, Netherlands Polish Forum of Organic Agriculture Réseau Environnement Santé (RES), France Sociedad Española de agricultura ecologica / Sociedad Española de agroecologia (SEAE) Task Force Italiana anti-ogm Union Nationale de l'apiculture Française XminY solidarity fund, Netherlands